Digital Health Weekly - 23 - 27 Feb, 2026

• Australians are waiting an average of 4.7 years to access life‑saving medical technologies due to outdated and complex reimbursement systems, according to a report by HTAnalysts and Edwards Lifesciences. 
• The report shows a growing inequity in patient care, with the UK, Germany and the US approving new devices in 1‑2 years versus nearly five years in Australia. 
• Delays are especially severe for heart‑disease patients, with about 1,500 public‑hospital patients each year missing potentially life‑saving valve surgery or TAVI procedures. 
• The authors call for urgent modernisation of Australia’s health‑technology assessment and reimbursement processes, recommending faster, provisional‑access models that collect real‑world data.

• Australian health AI company Heidi launched Heidi Evidence and Heidi Comms and acquired UK clinical AI firm Automedica, expanding its suite from AI‑generated notes to research, decision support, and patient communications. 
• Heidi Evidence delivers ad‑free, citation‑backed medical summaries within the consultation workflow, free for individual clinicians and subsidised by enterprise revenue. 
• Heidi Comms provides a team‑focused patient communications platform for calls, bookings, reminders, and follow‑ups to reduce missed appointments and streamline coordination. 
• The Automedica acquisition adds UK regulatory expertise, including access to the MHRA AI Airlock sandbox, strengthening Heidi’s compliance and UK market presence. 

• The Victorian government is supporting Melbourne Pathology’s new Centre of Excellence in Docklands, which will create over 450 jobs (200 construction, 250 permanent) and boost the state’s health‑tech sector. 
• The facility will house more than 10,000 m² of labs capable of processing 200,000 tests per day, expanding diagnostic capacity and adding advanced genomic testing and a drone landing pad for rapid sample transport. 
• With 700+ staff, the centre is expected to inject over $6 million annually into the Docklands economy and help position the precinct as a health‑innovation hub. 
• Construction is slated to begin later this year, marking a milestone for Victoria’s life‑sciences and advanced manufacturing growth.

• A recent Deloitte survey found that 85% of health system and health insurer technology executives plan to increase investment in agentic AI over the next two to three years, with 61% already building or implementing initiatives. 
• The executives expect agentic AI rollouts to drive significant efficiency gains and cost savings, with 98% anticipating at least 10% savings within 2 to 3 years, and 37% projecting savings exceeding 20% over that period. 
• Scaling generative and agentic AI across their organizations is a top strategic priority for health system and health plan leaders, second only to managing regulatory and policy changes. 
• Larger healthcare enterprises are better positioned to deploy and scale AI more aggressively than smaller players, but companies must define high‑value use cases, vet vendors, and implement strong governance frameworks.  

• Researchers at the University of Maryland have created a wearable device called Fartbit, a Fitbit‑style monitor that records the frequency and intensity of human flatulence. 
• The Fartbit is part of the Human Flatus Atlas project, which pairs the sensor with an app that requires participants to photograph everything they eat and drink to link diet with daily gas volume. 
• To test the prototype, the team built an artificial butt capable of releasing gas on command, allowing calibration of the sensor’s measurements. 
• The study aims to generate a comprehensive dataset on digestive health by analyzing correlations between recorded gas output and dietary intake

• Researchers at Tokyo University of Science, led by Associate Professor Isao Shitanda, have developed a water‑based “enzyme ink” that enables single‑step screen printing of enzymatic biofuel cells, removing labor‑intensive steps that hinder mass production. 
• The ink combines magnesium‑oxide‑templated mesoporous carbon, chemical mediators, a novel water‑based binder (POLYSOL), and target enzymes, producing electrodes that outperform conventional drop‑cast ones in catalytic current and stability. 
• A lactate/oxygen biofuel cell printed with this ink achieved a peak power density of 165 μW/cm² (0.63 V), sufficient to power Bluetooth Low Energy transmission for real‑time sweat lactate monitoring within physiological ranges (1–25 mM). 
• Roll‑to‑roll screen‑printing demonstrated scalability, with an estimated production cost of ~10 yen per disposable device, positioning the technology for low‑cost, large‑scale wearable biosensors expected to reach market around 2030.

• Oura is adding a new AI model to its Oura Advisor chatbot that focuses on women’s health, covering the full reproductive health spectrum from early menstrual cycles to menopause. 
• The model will be available soon to smart ring wearers, providing personalized health guidance via the Oura Advisor interface. 
• Oura states the AI model is hosted entirely on its own infrastructure, and user conversations are never sold, shared, or used to train public or third‑party AI systems. 
• The rollout emphasizes data privacy for sensitive reproductive health information, a key concern especially in markets like the United States. 

• Microchip Technology released a Fitness Tracker Wearables Reference Design to help engineers create low‑power health wearables with reliable biometric sensing and wireless data transmission. 
• The design integrates a 32‑bit MCU (options include SAM D21, SAM E51, or SAM L21) with an I²C heart‑rate sensor, a low‑power e‑ink display via SPI, and optional Bluetooth Low Energy (BLE) for real‑time mobile app streaming. 
• By providing a complete hardware and software foundation, the reference design shortens development cycles and enables reuse across fitness bands, smartwatches, and medical activity monitors. 
• Evaluation kits, BOM, schematics, and documentation are available, allowing rapid prototyping and customization for healthcare and fitness market products. 

• An eight‑hospital health system completed a system‑wide rollout of an FDA‑cleared wearable that continuously measures heart rate, respiratory rate and skin temperature across roughly 2,700 adult non‑ICU beds, with data fed directly into the EHR. 
• The phased implementation (2022‑2024) involved coordinated effort among clinical operations, IT, supply chain and unit leadership, and relied on a centralized virtual operations center for 24/7 alert monitoring and escalation. 
• Alert thresholds were refined during rollout—raising the upper heart‑rate limit, lowering the respiratory‑rate floor and dropping temperature as a single‑parameter trigger—reducing false positives and achieving >95% device utilization. 
• Nursing teams reported that continuous monitoring allowed extension of overnight vital‑sign intervals to every 6‑8 hours, saving an estimated 4 hours per shift and enabling staff to focus more on mobility and personal care. 

• Mind, the UK’s largest mental health charity, has launched a year‑long commission to examine AI reliability in mental health after a Guardian probe into Google’s AI Overviews. 
• The commission’s initial 20‑minute test uncovered “harmful inaccuracies,” including dangerous advice like “starvation is healthy” and validation of user delusions. 
• Rosie Weatherley, Mind’s information content manager, said AI Overviews replace nuanced, credible search results with clinical‑sounding, context‑free answers that appear definitive but are irresponsible. 
• The charity warns that such misleading AI output can harm distressed users who lack the ability to fact‑check, emphasizing the need for empathetic, nuanced information in the era of disinformation.